je.st
news
Tag: ligand
Ligand Pharmaceuticals Inc. (LGND) Stock Rating Reaffirmed by Roth Capital
2016-04-11 07:30:57| Biotech - Topix.net
's stock had its "buy" rating restated by equities research analysts at Roth Capital in a research report issued to clients and investors on Saturday, MarketBeat reports. Other hedge funds have made changes to their positions in the company.
Tags: rating
stock
capital
roth
Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval Of EVOMELA (melphalan) For Injection
2016-03-30 07:12:27| drugdiscoveryonline Home Page
Ligand Pharmaceuticals Incorporated announces thatSpectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) of EVOMELA
Tags: partner
approval
spectrum
receives
Want To Own The Biopharma Industry? Buy Ligand Pharmaceuticals
2016-03-28 17:34:50| Chemicals - Topix.net
I am always on the lookout for companies with sound business model especially those in the healthcare sector. Recently, I wrote about Cambrex and China Biologics which you can find here and here .
Tags: buy
industry
pharmaceuticals
ligand
Ligand Pharmaceuticals Inc. to Post Q1 2016 Earnings of $0.46 Per...
2016-02-16 05:34:10| Biotech - Topix.net
Ligand Pharmaceuticals Inc. - Equities research analysts at Craig Hallum upped their Q1 2016 earnings estimates for shares of Ligand Pharmaceuticals in a research report issued to clients and investors on Thursday, according to Zacks Investment Research . Craig Hallum analyst M. Tiampo now anticipates that the brokerage will post earnings of $0.46 per share for the quarter, up from their prior forecast of $0.44.
Tags: per
post
earnings
pharmaceuticals
Ligand Pharmaceuticals Lowered to Hold at Zacks
2015-08-23 17:16:33| Biotech - Topix.net
According to Zacks, "Ligand delivered better-than-expected second-quarter results with the company beating both top- and bottom-line estimates. Ligand's Captisol formulation technology has resulted in partnerships with several leading health care companies like Novartis, Amgen and Pfizer among others that provide the company with funds in the form of milestone and royalty payments.
Tags: hold
lowered
pharmaceuticals
ligand